Medically reviewed by Matthew Wosnitzer, MD Complement 3 glomerulopathy (C3G) is a rare kidney disease that is also ...

Dianthus Therapeutics, Inc. (DNTH) is advancing its potential best-in-class complement inhibitor drug DNTH103 for a wide variety of autoimmune disorders. In particular, it is looking at advancing the ...

In a phase three, double blind, placebo controlled trial, pegcetacoplan significantly reduced proteinuria compared with ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription.

The FDA granted accelerated approval to iptacopan (Fabhalta) for primary immunoglobulin A (IgA) nephropathy, a rare progressive disease where the immune system attacks the kidneys, Novartis announced ...

Dana Rizk, M.D., tenured professor of Medicine in the Division of Nephrology, has been named the latest recipient of the school’s Featured Discovery award. This recognition celebrates notable research ...